POZEN Logo
Print Page   Close Window

Press Release

POZEN Announces May 2, 2007 Webcast of First Quarter 2007 Results

CHAPEL HILL, N.C.--(BUSINESS WIRE)--April 18, 2007--POZEN Inc. (NASDAQ: POZN), announced today that it will release first quarter 2007 results on May 2, 2007, before the market opens.

The announcement will be followed by a live webcast at 11:00 a.m. Eastern Time with a discussion by POZEN management of the earnings and business results. The webcast can be accessed on POZEN's website at www.pozen.com and will be archived and available for replay. The first quarter 2007 earnings release can be accessed in the News section of POZEN's website.

POZEN is a pharmaceutical company committed to developing therapeutic advancements for diseases with unmet medical needs where it can improve efficacy, safety, and/or patient convenience. POZEN's efforts are focused primarily on the development of pharmaceutical products for the treatment of acute and chronic pain and other pain-related conditions. POZEN has development and commercialization alliances with GlaxoSmithKline for the proposed product candidate Trexima(TM) combining sumatriptan, formulated with RT Technology(TM), and naproxen sodium in a single tablet for the acute treatment of migraine, which is currently under review by the United States Food and Drug Administration, and with AstraZeneca for proprietary fixed dose combinations of naproxen with the proton pump inhibitor esomeprazole magnesium in a single tablet for conditions such as osteoarthritis and rheumatoid arthritis in patients who are at risk for developing NSAID-associated gastric ulcers. The company's common stock is traded on The Nasdaq Stock Market under the symbol "POZN". For detailed company information, including copies of this and other press releases, see POZEN's website: www.pozen.com.

CONTACT: POZEN
Bill Hodges, Chief Financial Officer
919-913-1030 or
Fran Barsky, Director, Investor Relations,
919-913-1044

SOURCE: POZEN Inc.